1
|
Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C, Inches J, Underwood D, Frost J, James A, Schofield C, James R, O’Reilly C, Sheridan R, Statton S, Goff A, Russell T, Whitcher A, Craw S, Lewis A, Sophia R, Amar K, Hernandez R, Pitcher A, Carvey S, Hamlin R, Lyell V, Aubry L, Carey G, Coebergh J, Mojela I, Molloy S, Berceruelo Bergaz Y, Camera B, Campbell P, Morris H, Samakomva T, Schrag A, Fuller S, Misbahuddin A, Parker L, Visentin E, Gallehawk S, Rudd J, Singh S, Wilson S, Creven J, Croucher Y, Tluk S, Watts P, Hargreaves S, Johnson D, Worboys L, Worth P, Brooke J, Kobylecki C, Parker V, Johnson L, Joseph R, Melville J, Raw J, Birt J, Hare M, Shaik S, Alty J, Cosgrove J, Burn D, Green A, McNichol A, Pavese N, Pilkington H, Price M, Walker K, Chaudhuri R, Podlewska A, Reddy P, Trivedi D, Bandmann O, Clegg R, Cole G, Emery A, Dostal V, Graham J, Keshet-Price J, Mamutse G, Miller-Fik A, Wiltshire A, Wright C, Dixon K, Abdelhafiz A, Rose J. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2022; 79:1232-1241. [PMID: 36315128 PMCID: PMC9623477 DOI: 10.1001/jamaneurol.2022.3718] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Importance Current treatments manage symptoms of Parkinson disease (PD), but no known treatment slows disease progression. Preclinical and epidemiological studies support the potential use of statins as disease-modifying therapy. Objective To determine whether simvastatin has potential as a disease-modifying treatment for patients with moderate PD. Design, Setting, and Participants This randomized clinical trial, a double-blind, parallel-group, placebo-controlled futility trial, was conducted between March 2016 and May 2020 within 23 National Health Service Trusts in England. Participants aged 40 to 90 years with a diagnosis of idiopathic PD, with a modified Hoehn and Yahr stage of 3.0 or less while taking medication, and taking dopaminergic medication with wearing-off phenomenon were included. Data were analyzed from May 2020 to September 2020, with additional analysis in February 2021. Interventions Participants were allocated 1:1 to simvastatin or matched placebo via a computer-generated random sequence, stratified by site and Hoehn and Yahr stage. In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvastatin, 80 mg daily, before a 2-month washout period. Main Outcomes and Measures The prespecified primary outcome was 24-month change in Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III score measured while not taking medication (high scores indicate worse outcome). The primary futility analysis included participants who commenced the 80-mg phase and had valid primary outcome data. The safety analysis included all participants who commenced trial treatment and is reported by dose at time of event. Results Of 332 patients assessed for eligibility, 32 declined and 65 were ineligible. Of 235 recruited participants, 97 (41%) were female, 233 (99%) were White, and the mean (SD) age was 65.4 (9.4) years. A total of 216 patients progressed to the 80-mg dose. Primary outcome analysis (n = 178) indicated the simvastatin group had an additional deterioration in MDS-UPDRS III score while not taking medication at 24 months compared with the placebo group (1.52 points; 2-sided 80% CI, -0.77 to 3.80; 1-sided futility test P = .006). A total of 37 serious adverse events (AEs), including 3 deaths, and 171 AEs were reported for participants receiving 0-mg simvastatin; 37 serious AEs and 150 AEs were reported for participants taking 40 mg or 80 mg of simvastatin. Four participants withdrew from the trial because of an AE. Conclusions and Relevance In this randomized clinical trial, simvastatin was futile as a disease-modifying therapy in patients with PD of moderate severity, providing no evidence to support proceeding to a phase 3 trial. Trial Registration ISRCTN Identifier: 16108482.
Collapse
Affiliation(s)
- Kara N. Stevens
- Faculty of Health, University of Plymouth, Plymouth, United Kingdom,Exploristics Ltd, Belfast, United Kingdom
| | - Siobhan Creanor
- College of Medicine and Health, University of Exeter, Exeter, United Kingdom
| | - Alison Jeffery
- Faculty of Health, University of Plymouth, Plymouth, United Kingdom
| | - Alan Whone
- Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - John Zajicek
- School of Medicine, Medical and Biological Sciences, University of St Andrews, St Andrews, United Kingdom
| | - Andy Foggo
- School of Biological and Marine Sciences, Faculty of Science and Engineering, University of Plymouth, Plymouth, United Kingdom
| | - Ben Jones
- College of Medicine and Health, University of Exeter, Exeter, United Kingdom
| | - Rebecca Chapman
- Faculty of Health, University of Plymouth, Plymouth, United Kingdom
| | - Laura Cocking
- NIHR BioResource, University of Cambridge, Cambridge, United Kingdom
| | - Jonny Wilks
- MAC Clinical Research, Blackpool, United Kingdom
| | - Doug Webb
- Bristol Trials Centre, University of Bristol, Bristol, United Kingdom
| | - Camille Carroll
- Faculty of Health, University of Plymouth, Plymouth, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Peddapatla RVG, Slevin C, Sheridan G, Beirne C, Swaminathan S, Browning I, O’Reilly C, Worku ZA, Egan D, Sheehan S, Crean AM. Modelling the Compaction Step of a Platform Direct Compression Process. Pharmaceutics 2022; 14:pharmaceutics14040695. [PMID: 35456529 PMCID: PMC9027228 DOI: 10.3390/pharmaceutics14040695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/06/2022] [Accepted: 03/16/2022] [Indexed: 02/01/2023] Open
Abstract
The ability to predict formulation behaviour at production scale during formulation design can reduce the time to market and decrease product development costs. However, it is challenging to extrapolate compaction settings for direct compression formulations between tablet press models during scale-up and transfer from R&D to commercial production. The aim of this study was to develop statistical process models to predict tablet tensile strength, porosity and disintegration time from compaction parameters (pre-compression and main compression force, and press speed), for three formulations, with differing deformation characteristics (plastic, brittle and elastic), on three tablet press models (one pilot-scale tablet press (KG RoTab) and two production-scale presses (Fette 1200i and GEA Modul P)). The deformation characteristics of yield pressure and elastic recovery were determined for the model placebo formulations investigated. To facilitate comparison of dwell time settings between tablet press models, the design of experiments (DoE) approach was 9 individual 16-run response surface DoEs (3 formulation × 3 press models), whose results were combined to create a polynomial regression model for each tablet property. These models predicted tablet tensile strength, porosity and disintegration time and enabled the construction of design spaces to produce tablets with specified target properties, for each formulation on each press. The models were successfully validated. This modelling approach provides an understanding of the compaction behaviour of formulations with varying deformation behaviour on development and commercial tablet press models. This understanding can be applied to inform achievable production rates at a commercial scale, during the formulation development.
Collapse
Affiliation(s)
- Raghu V. G. Peddapatla
- SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; (R.V.G.P.); (A.M.C.)
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
| | - Conor Slevin
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | - Gerard Sheridan
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | - Caoimhe Beirne
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
| | | | - Ivan Browning
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
| | - Clare O’Reilly
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
| | - Zelalem A. Worku
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
| | - David Egan
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | - Stephen Sheehan
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (C.S.); (G.S.); (C.B.); (I.B.); (C.O.); (Z.A.W.)
- Correspondence: ; Tel.: +353-877-413-140
| | - Abina M. Crean
- SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; (R.V.G.P.); (A.M.C.)
| |
Collapse
|
3
|
Wood A, Emery JD, Jenkins M, Chondros P, Campbell T, Wenkart E, O’Reilly C, Cowie T, Dixon I, Toner J, Khalajzadeh H, Gutierrez JM, Govan L, Buckle G, McIntosh JG. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program. Trials 2022; 23:31. [PMID: 35022080 PMCID: PMC8753594 DOI: 10.1186/s13063-021-05877-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 11/24/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Increasing participation in the Australian National Bowel Cancer Screening Program (NBCSP) is the most efficient and cost-effective way of reducing mortality associated with colorectal cancer by detecting and treating early-stage disease. Currently, only 44% of Australians aged 50-74 years complete the NBCSP. This efficacy trial aims to test whether this SMS intervention is an effective method for increasing participation in the NBCSP. Furthermore, a process evaluation will explore the barriers and facilitators to sending the SMS from general practice. METHODS We will recruit 20 general practices in the western region of Victoria, Australia to participate in a cluster randomised controlled trial. General practices will be randomly allocated with a 1:1 ratio to either a control or intervention group. Established general practice software will be used to identify patients aged 50 to 60 years old who are due to receive a NBCSP kit in the next month. The SMS intervention includes GP endorsement and links to narrative messages about the benefits of and instructions on how to complete the NBCSP kit. It will be sent from intervention general practices to eligible patients prior to receiving the NBCSP kit. We require 1400 eligible patients to provide 80% power with a two-sided 5% significance level to detect a 10% increase in CRC screening participation in the intervention group compared to the control group. Our primary outcome is the difference in the proportion of eligible patients who completed a faecal occult blood test (FOBT) between the intervention and control group for up to 12 months after the SMS was sent, as recorded in their electronic medical record (EMR). A process evaluation using interview data collected from general practice staff (GP, practice managers, nurses) and patients will explore the feasibility and acceptability of sending and receiving a SMS to prompt completing a NBCSP kit. DISCUSSION This efficacy trial will provide initial trial evidence of the utility of an SMS narrative intervention to increase participation in the NBCSP. The results will inform decisions about the need for and design of a larger, multi-state trial of this SMS intervention to determine its cost-effectiveness and future implementation. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12620001020976 . Registered on 17 October 2020.
Collapse
Affiliation(s)
- Anna Wood
- Centre for Cancer Research, University of Melbourne, Melbourne, Australia
- Department of General Practice, University of Melbourne, Melbourne, Australia
| | - Jon D. Emery
- Centre for Cancer Research, University of Melbourne, Melbourne, Australia
- Department of General Practice, University of Melbourne, Melbourne, Australia
| | - Mark Jenkins
- Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, Australia
| | - Patty Chondros
- Department of General Practice, University of Melbourne, Melbourne, Australia
| | | | | | | | - Tony Cowie
- Cancer Council Victoria, Melbourne, Australia
| | - Ian Dixon
- Consumer representative. Healthily Pty Ltd, Melbourne, Australia
| | - Julie Toner
- Consumer representative. Healthily Pty Ltd, Melbourne, Australia
| | - Hourieh Khalajzadeh
- Department of Software Systems & Cybersecurity, Monash University, Melbourne, Australia
| | - Javiera Martinez Gutierrez
- Centre for Cancer Research, University of Melbourne, Melbourne, Australia
- Department of General Practice, University of Melbourne, Melbourne, Australia
- Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Región Metropolitana, Chile
| | - Linda Govan
- Western Victoria Primary Health Network Ltd, Ballarat, Australia
| | | | - Jennifer G. McIntosh
- Centre for Cancer Research, University of Melbourne, Melbourne, Australia
- Department of Software Systems & Cybersecurity, Monash University, Melbourne, Australia
| |
Collapse
|
4
|
Peddapatla RVG, Sheridan G, Slevin C, Swaminathan S, Browning I, O’Reilly C, Worku ZA, Egan D, Sheehan S, Crean AM. Process Model Approach to Predict Tablet Weight Variability for Direct Compression Formulations at Pilot and Production Scale. Pharmaceutics 2021; 13:pharmaceutics13071033. [PMID: 34371725 PMCID: PMC8308976 DOI: 10.3390/pharmaceutics13071033] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/29/2021] [Accepted: 07/01/2021] [Indexed: 11/16/2022] Open
Abstract
Optimizing processing conditions to achieve a critical quality attribute (CQA) is an integral part of pharmaceutical quality by design (QbD). It identifies combinations of material and processing parameters ensuring that processing conditions achieve a targeted CQA. Optimum processing conditions are formulation and equipment-dependent. Therefore, it is challenging to translate a process design between formulations, pilot-scale and production-scale equipment. In this study, an empirical model was developed to determine optimum processing conditions for direct compression formulations with varying flow properties, across pilot- and production-scale tablet presses. The CQA of interest was tablet weight variability, expressed as percentage relative standard deviation. An experimental design was executed for three model placebo blends with varying flow properties. These blends were compacted on one pilot-scale and two production-scale presses. The process model developed enabled the optimization of processing parameters for each formulation, on each press, with respect to a target tablet weight variability of <1%RSD. The model developed was successfully validated using data for additional placebo and active formulations. Validation formulations were benchmarked to formulations used for model development, employing permeability index values to indicate blend flow.
Collapse
Affiliation(s)
- Raghu V. G. Peddapatla
- SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; (R.V.G.P.); (A.M.C.)
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
| | - Gerard Sheridan
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | - Conor Slevin
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | | | - Ivan Browning
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
| | - Clare O’Reilly
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
| | - Zelalem A. Worku
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
| | - David Egan
- Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland;
| | - Stephen Sheehan
- Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; (G.S.); (C.S.); (I.B.); (C.O.); (Z.A.W.)
- Correspondence: ; Tel.: +353-877-413-140
| | - Abina M. Crean
- SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; (R.V.G.P.); (A.M.C.)
| |
Collapse
|
5
|
Cooke G, Kamal I, Strengert M, Hams E, Mawhinney L, Tynan A, O’Reilly C, O’Dwyer DN, Kunkel SL, Knaus UG, Shields DC, Moller DR, Bowie AG, Fallon PG, Hogaboam CM, Armstrong ME, Donnelly SC. Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis. QJM 2018; 111:217-224. [PMID: 29237089 PMCID: PMC6256937 DOI: 10.1093/qjmed/hcx243] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 11/30/2017] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND/INTRODUCTION Sarcoidosis is a multi-systemic disorder of unknown etiology, characterized by the presence of non-caseating granulomas in target organs. In 90% of cases, there is thoracic involvement. Fifty to seventy percent of pulmonary sarcoidosis patients will experience acute, self-limiting disease. For the subgroup of patients who develop persistent disease, no targeted therapy is currently available. AIM To investigate the potential of the single nucleotide polymorphism (SNP), Toll-like receptor 3 Leu412Phe (TLR3 L412F; rs3775291), as a causative factor in the development of and in disease persistence in pulmonary sarcoidosis. To investigate the functionality of TLR3 L412F in vitro in primary human lung fibroblasts from pulmonary sarcoidosis patients. DESIGN SNP-genotyping and cellular assays, respectively, were used to investigate the role of TLR3 L412F in the development of persistent pulmonary sarcoidosis. METHODS Cohorts of Irish sarcoidosis patients (n = 228), healthy Irish controls (n = 263) and a secondary cohort of American sarcoidosis patients (n = 123) were genotyped for TLR3 L412F. Additionally, the effect of TLR3 L412F in primary lung fibroblasts from pulmonary sarcoidosis patients was quantitated following TLR3 activation in the context of cytokine and type I interferon production, TLR3 expression and apoptotic- and fibroproliferative-responses. RESULTS We report a significant association between TLR3 L412F and persistent clinical disease in two cohorts of Irish and American Caucasians with pulmonary sarcoidosis. Furthermore, activation of TLR3 in primary lung fibroblasts from 412 F-homozygous pulmonary sarcoidosis patients resulted in reduced IFN-β and TLR3 expression, reduced apoptosis- and dysregulated fibroproliferative-responses compared with TLR3 wild-type patients. DISCUSSION/CONCLUSION This study identifies defective TLR3 function as a previously unidentified factor in persistent clinical disease in pulmonary sarcoidosis and reveals TLR3 L412F as a candidate biomarker.
Collapse
Affiliation(s)
- G Cooke
- Department of Applied Sciences, Institute of Technology Tallaght,
Tallaght, Dublin 24, Ireland
| | - I Kamal
- School of Medicine and Medical Science, College of Life Sciences, UCD
Conway Institute of Biomolecular and Biomedical Research, University College Dublin,
Belfield, Dublin 4, Ireland
- National Pulmonary Fibrosis Referral Centre at St. Vincent’s University
Hospital, Elm Park, Dublin 4, Ireland
| | - M Strengert
- School of Medicine and Medical Science, College of Life Sciences, UCD
Conway Institute of Biomolecular and Biomedical Research, University College Dublin,
Belfield, Dublin 4, Ireland
| | - E Hams
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
- National Children’s Research Centre, Our Lady’s Children’s Hospital
Crumlin, Dublin 12, Ireland
| | - L Mawhinney
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
| | - A Tynan
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
| | - C O’Reilly
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
| | - D N O’Dwyer
- School of Medicine and Medical Science, College of Life Sciences, UCD
Conway Institute of Biomolecular and Biomedical Research, University College Dublin,
Belfield, Dublin 4, Ireland
- National Pulmonary Fibrosis Referral Centre at St. Vincent’s University
Hospital, Elm Park, Dublin 4, Ireland
| | - S L Kunkel
- Department of Pathology, University of Michigan Medical School, Ann
Arbor, MI 48109, USA
| | - U G Knaus
- School of Medicine and Medical Science, College of Life Sciences, UCD
Conway Institute of Biomolecular and Biomedical Research, University College Dublin,
Belfield, Dublin 4, Ireland
| | - D C Shields
- UCD Complex and Adaptive Systems Laboratory, University College Dublin,
Belfield, Dublin 4, Ireland
| | - D R Moller
- Division of Pulmonary and Critical Care Medicine, Department of
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - A G Bowie
- School of Biochemistry and Immunology, Trinity Biomedical Sciences
Institute, Trinity College, Dublin 2, Ireland
| | - P G Fallon
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
- National Children’s Research Centre, Our Lady’s Children’s Hospital
Crumlin, Dublin 12, Ireland
| | - C M Hogaboam
- Department of Pathology, University of Michigan Medical School, Ann
Arbor, MI 48109, USA
| | - M E Armstrong
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
| | - S C Donnelly
- School of Medicine, Trinity Biomedical Sciences Institute, Trinity
College, Dublin 2, Ireland
- Department of Clinical Medicine, Trinity Centre for Health Sciences,
Tallaght Hospital, Tallaght, Dublin 24, Ireland
| |
Collapse
|
6
|
O’Connor L, O’Leary M, Leonard N, Godinho M, O’Reilly C, Egan J, O’Mahony R. The characterization of Listeria spp. isolated from food products and the food-processing environment. Lett Appl Microbiol 2010; 51:490-8. [DOI: 10.1111/j.1472-765x.2010.02928.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Cullinane A, Coca-Prados M, Harvey B, O’Reilly C, Ryan MP, Maguire D, O’Sullivan G, Harvey BJ, Gebruers EM, Hall WJ, Harris AM, O’Halloran KD, Curran AK, Bradford A, Bunting HE, McConaghy P, McLoughlin C, Sweeney D, Hardiman O, Grealy M, Sreenan JM, Gilmartin L, O’Cuinn G, Lawlor M, O’Boyle KM, Farrell CB, Foster NEL, Walsh DM, Baxter GD, Allen JM, Cawley T, Breslin E, Docherty JR, Hynes AC, Kane MT, Duffy C, Mohd Nor A, Johnson AH, Tomkin GH, Collins PB, Crónín DÓ, McCloskey S, Thornbury KD, O’Rourke M, Kearns S, Campion DP, Leek BF, Curran AK, Curran AK, O’Regan RG, McLaughlin N, Curran AK, Gaffney J, Edgell TA, Walker JM, MacSweeney CP, Faherty C, Kelly JP, Leonard BE, Earley B, O’Neill M, Reymann JM, Allain H, Caldwell M, Jennings M, Prosser E, Urbach V, Horwitz E, Horwitz ER, Presser E, Raffin JP, Thomas S, Egan DA, O’Farrell A. Royal academy of medicine in Ireland section of biomedical sciences Proceedings of Summer Meeting held June, 1994. Ir J Med Sci 1995. [DOI: 10.1007/bf02968123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Kent A, Keenan AK, Herity NA, Allen JD, Silke B, Adgey AAJ, O’Halloran KD, Curran AK, Bradford A, Craig JA, Barlas P, Baxter GD, Walsh DM, Allen JM, Logan ID, Wilkinson YA, McKenna PG, Brayden DJ, Dunne J, Baird AW, Kelly JG, O’Connor JJ, Rowan MJ, Anwyl R, Caldwell M, Earley B, Leonard BE, Wedlock PM, Shephard RA, Bracken PJ, Fitzpatrick JM, O’Reilly C, Quinn E, Ryan MP, O’Neill J, Kernan RP, Craven CD, Healy E, Clarke H, Nolan CA, O’Connell C, Deegan PM, Abdelwahab YHA, Barnett CR, Flatt PR, MacSweeney C, Kelly JP, Cawley T, Geraghty J, Osborne H, Docherty JR, Nelson AA, McDowell BC, McCrory M, Deasy PB, Finan MP, Klatt PR, Hornykiewytsch T, Campion DP, Leek BF, Sharma SC, Barry-Kinsella C, Foran K, Thomas G, McKinney MW, O’Connor J, McKelvey-Martin VJ, Thompson CCM, McCarthy PJ, Hannigan BM, Thurnham DI, Chopra M, Leake D, Sheehy PJA, Delanty N, Murphy N, Lawson JA, FitzGerald GA, Fitzgerald DJ, Smyth EM, McCole D, O’Neill M, Canney M, Turley E, Strain JJ, Gallagher GA, Shields TD, O’Kane S, Eason SJ, Gilmore WS, King CM, Hejmadi M, McKeown SR, McAleer JJA, Patterson LH, Gray PSC, Lappin TRJ, Bridges JM, Richardson SAM, Murphy PG, Davidson N, Hooper ACB. Royal Academy of Medicine in Ireland Section of Biomedical Sciences Proceedings of Summer Meeting held 22nd & 23rd June, 1993. Ir J Med Sci 1994. [DOI: 10.1007/bf02965965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|